Ausgewählte Publikationen

Wildner G.
Antigenic mimicry – the key to autoimmunity in immune privileged organs
J. Autoimmunity 2022, https://doi.org/10.1016/j.jaut.2022.102942

Alfaar AS, Stürzbecher L, Diedrichs-Möhring M, Lam M, Roubeix C, Ritter J, Schumann K, Annamalai B, Pompös, I-M, Rohrer B, Sennlaub F, Reichhart N, Wildner G, Strauß O.
FoxP3 expression by retinal pigment epithelial cells: stress induced factor with potential relevance for the pathology of age-related macular degeneration. J. Neuroinflamm. 19:260 (2022) https://doi.org/10.1186/s12974-022-02620-w

Thurau s, Deuter C, Heiligenhaus A, Pleyer U, Van Calster J, Barisani-Asenbauer T, Obermayr F, Sperl S, Seda-Zehetner R, Wildner G.
A new small molecule DHODH-inhibitor (KIO-100 (PP-001)) targeting activated T cells for intraocular treatment of uveitis -a phase I clinical trial. Front. Med. 1023224 (2022). DOI: 10.3389/fmed.2022.1023224

Gehrke M, Diedrichs-Möhring M, Bogedein J, Büning H, Michalakis S, Wildner G.
Immunogenicity of novel AAV Capsids for retinal gene therapy.
Cells 11:1881 (2022) doi.org/10.3390/cells11121881

Thurau S, Engelke H, McCluskey P, Symes RJ, Whist E, Teuchner B, Haas G, Allegri P, Cimino L, Bolletta E, Miserocchi E, Russo M, Li JQ, Heiligenhaus A, Wildner G.
Uveitis in tumor patients treated with immunological checkpoint- and signal transduction pathway-inhibitors. Ocul Immunol Inflamm 30:1588-1594 (2022), doi.org/10.1080/09273948.2021.1910850

Wildner G.
Tumors, tumor therapies, autoimmunity and the eye. Autoimmun Rev 2021 20(9):102892.
doi: 10.1016/j.autrev.2021.102892.

Wildner G, Diedrichs-Möhring, M.
Mimicry in uveitis. Front Immunol. 2020; Oct 29;11:580636. doi:10.3389/fimmu.2020.580636.eCollection 2020

Wakefield D, Wildner G.
Is glaucoma an autoimmune disease? Clin Transl Immunology. 2020; 9; e1180. doi: 10.1002/cti2.1180

Wildner G, Diedrichs-Möhring, M.
Resolution of uveitis. Sem. Immunopathol 41:727-736 (2019) https://doi.org/10.1007/s00281-019-00758-z

Diedrichs-Möhring, M., Kaufmann, U., Wildner, G.
The immunopathogenesis of chronic and relapsing autoimmune uveitis – lessons from experimental rat models. Prog. Retin. Eye Res. 65:107-126 (2018) doi.org/10.1016/j.preteyeres.2018.02.003

Diedrichs-Möhring, M., Niesik, S., Priglinger, C.S., Thurau, S.R., Obermayr, F., Sperl, S., Wildner, G.
Intraocular DHODH-inhibitor PP-001 suppresses relapsing experimental uveitis and cytokine production of human lymphocytes, but not of RPE cells. J. Neuroinflammation 15:54 (2018)

Busch, C., Annamalai B., Khava, A., Reichhart, N., Huber, C., Lin, Y., Jo, E.A., Zipfel, P.F., Skerka, C., Wildner, G., Diedrichs-Möhring, M., Rohrer, B., Strauß, O.
Anaphylatoxins activate Ca2+, Akt/PI3-kinase and FOXO1/FoxP3 in the retinal pigment epithelium. Front. Immunol: 15 June 2017 | https://doi.org/10.3389/fimmu.2017.00703